3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
75
Precursor Cell Lymphoblastic Leukemia-Lymphoma
67
Leukemia, Lymphocytic, Chronic, B-Cell
59
Lymphoma, Non-Hodgkin
57
Hodgkin Disease
55
Multiple Myeloma
54
Myelodysplastic Syndromes
52
Leukemia
45
Lymphoma, Mantle-Cell
42
Lymphoma, Follicular
39
Lymphoma, Large B-Cell, Diffuse
36
Lymphoma
36
Lymphoma, B-Cell, Marginal Zone
35
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
35
Myeloproliferative Disorders
32
Leukemia, Myelomonocytic, Chronic
31
Burkitt Lymphoma
31
Congenital Abnormalities
28
Lymphoma, Large-Cell, Immunoblastic
27
Waldenstrom Macroglobulinemia
26
Leukemia, Myeloid, Chronic-Phase
25
Leukemia, Myeloid, Accelerated Phase
23
Lymphoma, T-Cell, Cutaneous
21
Recurrence
20
Primary Myelofibrosis
20
Lymphoma, Large-Cell, Anaplastic
19
Dendritic Cell Sarcoma, Interdigitating
19
Hematologic Neoplasms
18
Blast Crisis
18
Anemia, Refractory, with Excess of Blasts
18
Interventions
dacetuzumab
6
blinatumomab
6
Rituximab
4
Epoetin Alfa
4
Lenalidomide
3
Dexamethasone
3
Darbepoetin alfa
3
Cyclophosphamide
3
Bortezomib
3
Therapeutics
2
Everolimus
2
Early Intervention, Educational
2
Alemtuzumab
2
venetoclax
1
vandetanib
1
tirbanibulin
1
tetulomab tetraxetan lu-177
1
ponatinib
1
plerixafor
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
imetelstat
1
ibrutinib
1
fludarabine
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoproliferative Disorders
×
Whole-Body Irradiation
×
Clear all
NCT00368355
2020-01-21
MOHEL
Baylor College of Medicine
Phase 2
Completed
46 enrolled
12 charts